Literature DB >> 14749671

The presence and function of phosphodiesterase type 5 in the rat myometrium.

Catalin S Buhimschi1, Robert E Garfield, Carl P Weiner, Irina A Buhimschi.   

Abstract

OBJECTIVE: Cyclic nucleotide phosphodiesterases (PDEs) are a diverse enzyme group with multiple regulatory properties and wide tissue distribution. Such activity includes cyclic adenosine (cAMP) and guanosine monophosphate (cGMP) breakdown. The type 5 isoform (PDE-5, cGMP specific) is the target of specific antagonists (ie, sildenafil, Viagra). We tested the hypothesis that PDE-5 is present in rat myometrium and modulates myometrial activity. STUDY
DESIGN: Full-thickness uterine wall was collected from nonpregnant (n=3) and pregnant Sprague-Dawley rats on days 10 (n=4), 17 (n=6), 22 nonlabor (n=5), and 22 during term labor (TL, n=4). Preterm labor (PTL, n=3) was induced in some animals on day 16 with 15 mg/kg mifepristone (RU 486). Tissue samples were prepared for Western blotting using a monoclonal antibody against rodent PDE-5. In a second series, cumulative doses of sildenafil (0.005, 0.05, 0.5, 5 mg/kg, intraperitoneal) were administered and the effect on uterine contractility recorded in vivo during term (TL, n=7) and preterm labor (PTL, n=6). Saline solution-injected rats provided temporal control. Uterine contractility was estimated from intrauterine pressure (IP) measured electronically with a sensor tip pressure catheter. Heart rate was recorded simultaneously using electrodes attached to the chest and connected to the same data acquisition system.
RESULTS: PDE-5 immunoreactivity was present in the nonpregnant rat uterus and at all gestational times studied, although the expression was unaffected by either pregnancy or the state of labor (preterm or term). A dominant antibody-specific band was identified at 86 kd in the uterine samples, contrasting with lung where the 100-kd PDE-5 isoform was most abundant. Two additional lower molecular weight (55 and 32 kd) bands were also identified as antibody specific. Despite the lack of change in PDE-5 during pregnancy, sildenafil reduced IP during TL and PTL beginning at 0.5 mg/kg. The highest dose of sildenafil reduced IP during both TL and PTL by 45% and 59% of baseline, respectively (two-way analysis of variance, P<.01). This effect was not accompanied by changes in heart rate.
CONCLUSION: PDE-5 is constitutively present in the rat uterine wall. There was no observed change in the PDE-5 protein expression throughout pregnancy. In contrast to the lung, the uterus expresses an 80-kd PDE-5 isoform. Sildenafil in pharmacologic doses inhibits mechanical uterine activity and might be of benefit if selectively used for treatment of preterm labor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14749671     DOI: 10.1016/j.ajog.2003.07.006

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

1.  In Vivo Genome-Wide PGR Binding in Pregnant Human Myometrium Identifies Potential Regulators of Labor.

Authors:  Ariel J Dotts; Derek Reiman; Ping Yin; Stacy Kujawa; William A Grobman; Yang Dai; Serdar E Bulun
Journal:  Reprod Sci       Date:  2022-06-22       Impact factor: 3.060

2.  Myometrial progesterone receptor determines a transcription program for uterine remodeling and contractions during pregnancy.

Authors:  San-Pin Wu; Tianyuan Wang; Zheng-Chen Yao; Mary C Peavey; Xilong Li; Lecong Zhou; Irina V Larina; Francesco J DeMayo
Journal:  PNAS Nexus       Date:  2022-08-19

3.  Sildenafil citrate in the treatment of pain in primary dysmenorrhea: a randomized controlled trial.

Authors:  R Dmitrovic; A R Kunselman; R S Legro
Journal:  Hum Reprod       Date:  2013-08-06       Impact factor: 6.918

Review 4.  Sildenafil during the 2nd and 3rd Trimester of Pregnancy: Trials and Tribulations.

Authors:  Felix Rafael De Bie; David Basurto; Sailesh Kumar; Jan Deprest; Francesca Maria Russo
Journal:  Int J Environ Res Public Health       Date:  2022-09-06       Impact factor: 4.614

5.  Effects and mechanisms of action of sildenafil citrate in human chorionic arteries.

Authors:  Chrisen H Maharaj; Daniel O'Toole; Tadhg Lynch; John Carney; James Jarman; Brendan D Higgins; John J Morrison; John G Laffey
Journal:  Reprod Biol Endocrinol       Date:  2009-04-23       Impact factor: 5.211

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.